Bridgeway Capital Management, LLC Marker Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.26 - $0.46 $19,500 - $34,500	-75,000 Reduced 23.13%	249,216 $82,000
Q4 2021 Feb 14, 2022	BUY	$0.95 - $1.72 $33,250 - $60,200	35,000 Added 12.1%	324,216 $308,000
Q3 2021 Nov 15, 2021	BUY	$1.68 - $2.88 $213,360 - $365,760	127,000 Added 78.29%	289,216 $489,000
Q2 2021 Aug 16, 2021	SELL	$1.88 - $3.56 $54,249 - $102,727	-28,856 Reduced 15.1%	162,216 $453,000
Q1 2021 May 17, 2021	SELL	$1.47 - $3.29 $10,501 - $23,503	-7,144 Reduced 3.6%	191,072 $428,000
Q4 2020 Feb 16, 2021	SELL	$1.36 - $1.75 $34,000 - $43,750	-25,000 Reduced 11.2%	198,216 $287,000
Q2 2020 Aug 14, 2020	BUY	$1.69 - $2.79 $377,235 - $622,772	223,216 New	223,216 $462,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $228M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.